← Back to all signals
RESEARCH PAPER ANALYSIS

Hippocampal-striatal interaction in Parkinson's disease with mild cognitive impairment.

This PET and MRI study of 53 PD patients finds that asymmetry of striatal VMAT2 uptake and hippocampal CA2/3 subfield volumes are associated with cognitive impairment and interact to predict global cognition, especially in PD-MCI.

PMID42016529
JournalClinical parkinsonism & related disorders
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This PET and MRI study of 53 PD patients finds that asymmetry of striatal VMAT2 uptake and hippocampal CA2/3 subfield volumes are associated with cognitive impairment and interact to predict global cognition, especially in PD-MCI.

WHY IT MATTERS

Research significance

Provides candidate imaging biomarkers (striatal dopaminergic and hippocampal subfield asymmetry) that could aid stratification and endpoint selection for trials targeting cognitive decline in PD, though results are exploratory and sample-limited.

ABSTRACT

Source abstract

BACKGROUND: Striatal dopaminergic dysfunction and hippocampal degeneration contribute to cognitive impairment in Parkinson's disease (PD). However, their interaction in PD-related cognitive decline remains unclear. OBJECTIVE: We aimed to investigate whether asymmetry of striatal dopaminergic integrity and hippocampal subfield volume are associated with cognitive performance in PD, and whether their statistical interaction provides additional explanatory value. METHODS: A cohort of 53 participants from the Parkinson's Progression Markers Initiative (PPMI) was analyzed, including 33 PD with mild cognitive impairment (PD-MCI) patients and 20 PD with normal cognition (PD-NC) patients. All patients had complete 18F-AV-133 vesicular monoamine transporter 2 PET and 3D-T1w imaging. Asymmetry indices (AI) were calculated for striatal 18F-AV-133 standard uptake volume ratio (SUVR) and hippocampal subfield volumes. RESULTS: PD-MCI showed higher AI in caudate and anterior putamen uptake versus PD-NC. Hippocampal CA2/3 and granule cell layer AI correlated with MoCA. Caudate and anterior putamen uptake AI linked to multiple cognitive domains. Regression analysis revealed interactions between anterior putamen SUVR AI and CA2/3 AI on MoCA in PD (p = 0.039), and posterior putamen SUVR AI with CA2/3 AI on MoCA in PD-MCI (p = 0.002). CONCLUSION: Striatal dopaminergic asymmetry and hippocampal subfield asymmetry are both associated with cognitive impairment in PD. In exploratory regression models, the association between CA2/3 asymmetry and global cognition varied according to the degree of striatal dopaminergic asymmetry. These findings clarified the relationship between hippocampus and dopaminergic pathways in PD with cognitive decline, and deepen understanding of the pathophysiological mechanisms of cognitive impairment.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic